Ginkgo Bioworks announced on July 17, 2025, the launch of a new high-throughput, low-cost ADME (Absorption, Distribution, Metabolism, and Excretion) profiling service through its Ginkgo Datapoints offering. This new capability leverages Ginkgo's proprietary Reconfigurable Automation Cart (RAC) automation.
The service is performed entirely in the United States and aims to match or beat the pricing quotes from Chinese or other international vendors. This strategic positioning offers biopharma companies a domestic option for critical preclinical testing.
The ADME profiling service provides high-quality readouts for microsomal stability, kinetic solubility, P450 inhibition, and permeability, with optional in vitro toxicity assessments. This expansion enhances Ginkgo's service portfolio and addresses a key need in small molecule drug discovery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.